Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19).


Journal

Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101

Informations de publication

Date de publication:
01 04 2021
Historique:
received: 15 01 2021
accepted: 29 01 2021
pubmed: 10 2 2021
medline: 7 4 2021
entrez: 9 2 2021
Statut: ppublish

Résumé

To describe coronavirus disease 2019 (COVID-19) severity in pregnant patients and evaluate the association between disease severity and perinatal outcomes. We conducted an observational cohort study of all pregnant patients with a singleton gestation and a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who delivered at 1 of 33 U.S. hospitals in 14 states from March 1 to July 31, 2020. Disease severity was classified by National Institutes of Health criteria. Maternal, fetal, and neonatal outcomes were abstracted by centrally trained and certified perinatal research staff. We evaluated trends in maternal characteristics and outcomes across COVID-19 severity classes and associations between severity and outcomes by multivariable modeling. A total of 1,219 patients were included: 47% asymptomatic, 27% mild, 14% moderate, 8% severe, 4% critical. Overall, 53% were Hispanic; there was no trend in race-ethnicity distribution by disease severity. Those with more severe illness had older mean age, higher median body mass index, and pre-existing medical comorbidities. Four maternal deaths (0.3%) were attributed to COVID-19. Frequency of perinatal death or a positive neonatal SARS-CoV-2 test result did not differ by severity. Adverse perinatal outcomes were more frequent among patients with more severe illness, including 6% (95% CI 2-11%) incidence of venous thromboembolism among those with severe-critical illness compared with 0.2% in mild-moderate and 0% in asymptomatic (P<.001 for trend across severity). In adjusted analyses, severe-critical COVID-19 was associated with increased risk of cesarean birth (59.6% vs 34.0%, adjusted relative risk [aRR] 1.57, 95% CI 1.30-1.90), hypertensive disorders of pregnancy (40.4% vs 18.8%, aRR 1.61, 95% CI 1.18-2.20), and preterm birth (41.8% vs 11.9%, aRR 3.53, 95% CI 2.42-5.14) compared with asymptomatic patients. Mild-moderate COVID-19 was not associated with adverse perinatal outcomes compared with asymptomatic patients. Compared with pregnant patients with SARS-CoV-2 infection without symptoms, those with severe-critical COVID-19, but not those with mild-moderate COVID-19, were at increased risk of perinatal complications.

Identifiants

pubmed: 33560778
doi: 10.1097/AOG.0000000000004339
pii: 00006250-202104000-00003
pmc: PMC7984765
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-580

Subventions

Organisme : NICHD NIH HHS
ID : UG1 HD027869
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040560
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087230
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD053097
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD027869
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040545
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040485
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040500
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027915
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087192
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040544
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD034208
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040512
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD036801
Pays : United States
Organisme : NICHD NIH HHS
ID : U24 HD036801
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

Financial Disclosure: Torri Metz is the site Principal Investigator (PI) for a Pfizer RSV vaccination study, a Novavax RSV vaccination study, and a Gestvision study of the validity of a point-of-care preeclampsia test. She also receives royalties for two UpToDate topics on vaginal birth after cesarean. Brenna Hughes disclosed receiving funds from Merck. Cynthia Gyamfi-Bannerman disclosed that money was paid to her institution from NICHD/NHLBI and AMAG/SMFM. She has received funds from Sera Prognostics as a Medical Advisory Board Member. Alan Tita reports money was paid to his institution from Pfizer. The other authors did not report any potential conflicts of interest.

Références

Khoury R, Bernstein PS, Debolt C, Stone J, Sutton DM, Simpson LL, et al. Characteristics and outcomes of 241 births to women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at five New York City medical centers. Obstet Gynecol 2020;136:273–82. doi: 10.1097/AOG.0000000000004025
doi: 10.1097/AOG.0000000000004025
Griffin I, Benarba F, Peters C, Oyelese Y, Murphy T, Contreras D, et al. The impact of COVID-19 infection on labor and delivery, newborn nursery, and neonatal intensive care unit: prospective observational data from a single hospital system. Am J Perinatol 2020;37:1022–30. doi: 10.1055/s-0040-1713416
doi: 10.1055/s-0040-1713416
Afshar Y, Gaw SL, Flaherman VJ, Chambers BD, Krakow D, Berghella V, et al. Clinical presentation of coronavirus disease-2019 (COVID-19) in pregnant and recently pregnant people. Obstet Gynecol 2020;136:1117–25. doi: 10.1097/AOG.0000000000004178
doi: 10.1097/AOG.0000000000004178
Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, et al. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG 2020;127:1548–56. doi: 10.1111/1471-0528.16403
doi: 10.1111/1471-0528.16403
Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320. doi: 10.1136/bmj.m3320
doi: 10.1136/bmj.m3320
Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. Accessed January 12, 2020. https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e3.htm
Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. JAMA Netw Open 2020;3:e2029256. doi: 10.1001/jamanetworkopen.2020.29256
doi: 10.1001/jamanetworkopen.2020.29256
National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Accessed January 27, 2021. https://www.covid19treatmentguidelines.nih.gov
Postpartum hemorrhage. Practice Bulletin No. 183. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e168–86. doi: 10.1097/AOG.0000000000002351
doi: 10.1097/AOG.0000000000002351
Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists. Obstet Gynecol 2020;135:e237–260. doi: 10.1097/AOG.0000000000003891
doi: 10.1097/AOG.0000000000003891
Cnattingius S, Johansson S, Razaz N. Apgar score and risk of neonatal death among preterm infants. N Engl J Med 2020;383:49–57. doi: 10.1056/NEJMoa1915075
doi: 10.1056/NEJMoa1915075
Duryea EL, Hawkins JS, McIntire DD, Casey BM, Leveno KJ. A revised birth weight reference for the United States. Obstet Gynecol 2014;124:16–22. doi: 10.1097/AOG.0000000000000345
doi: 10.1097/AOG.0000000000000345
Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020;18:1859–65. doi: 10.1111/jth.14929
doi: 10.1111/jth.14929
Blumberg DA, Underwood MA, Hedriana HL, Lakshminrusimha S. Vertical transmission of SARS-CoV-2: what is the optimal definition? Am J Perinatol 2020;37:769–72. doi: 10.1055/s-0040-1712457
doi: 10.1055/s-0040-1712457
Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22 to June 7, 2020. MMWR Morb Mortal Wkly Rep 2020;69:769–75. doi: 10.15585/mmwr.mm6925a1
doi: 10.15585/mmwr.mm6925a1
Jering KS, Claggett BL, Cunningham JW, Rosenthal N, Vardeny O, Greene MF, et al. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. JAMA Int Med;2021 Jan 15 [Epub ahead of print]. doi: 10.1001/jamainternmed.2020.9241
doi: 10.1001/jamainternmed.2020.9241

Auteurs

Torri D Metz (TD)

Departments of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, University of Texas Medical Branch at Galveston, Galveston, Texas, Northwestern University, Chicago, Illinois, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, Columbia University, New York, New York, University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston, Texas, University of Pennsylvania, Philadelphia, Pennsylvania, Brown University, Providence, Rhode Island, University of Alabama at Birmingham, Birmingham, Alabama, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, The Ohio State University, Columbus, Ohio, University of Pittsburgh, Pittsburgh, Pennsylvania, and University of Texas at Austin, Austin, Texas; the George Washington University Biostatistics Center, Washington, DC; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH